Adjuvant therapy in the elderly: Making the right decision

Journal of Clinical Oncology

Volumn 25, Issue 14, 2007, Pages 1870-1875

  Muss, Hyman B ^a   Biganzoli, Laura ^a   Sargent, Daniel J ^a   Aapro, Matti ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; OXALIPLATIN; PLATINUM COMPLEX; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGING; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMORBIDITY; ELDERLY CARE; GERIATRIC ASSESSMENT; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MENTAL DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PATIENT SELECTION;

EID: 34249826935     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3457     Document Type: Review

References (60)

1. Devesa S: The burden of cancer in the elderly, in Muss HB, Hunter CP, Johnson KA (eds): Treatment and Management of Cancer in the Elderly. New York, NY, Taylor and Francis, 2006, pp 7-28
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
5. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
6. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
7. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA 17. J Natl Cancer Inst 97:1262-1271, 2005
8. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
9. International Breast Cancer Study Group: Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 94:1054-1065, 2002
10. Fisher B, Jeong JH, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004
11. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
12. Paik S: Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res 12:1019s-1023s, 2006
13. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005
14. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21:4524-4531, 2003
15. Giordano SH, Duan Z, Kuo YF, et al: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750-2756, 2006
16. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
17. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
18. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
19. Wolmark N, Wieand HS, Kuebler JP, et al: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol 23:246s, 2005 (abstr LBA3500)
20. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
21. Dobie SA, Baldwin LM, Dominitz JA, et al: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98:610-619, 2006
22. Sargent DJ, Goldberg RM, Jacobsen SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
23. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006
24. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005
25. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002
26. Iwashyna TJ, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20:3992-3998, 2002
27. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005
28. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
29. Henschke CI, Yankelevitz DF, Libby DM, et al: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355:1763-1771, 2006
30. Unger M: A pause, progress, and reassessment in lung cancer screening. N Engl J Med 355:1822-1824, 2006
31. Alam N, Darling G, Evans WK, et al: Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review. Crit Rev Oncol Hematol 58:146-155, 2006
32. Hamada C, Tanaka F, Ohta M, et al: Metaanalysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006, 2005
33. Gridelli C, Maione P, Rossi A: Treatment of stage l-lll non-small-cell lung cancer in the elderly. Oncology (Williston Park) 20:373-380, 2006
34. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
35. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006
36. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
37. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998
38. Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: Competing causes of mortality - International Breast Cancer Study Group. J Clin Oncol 8:519-526, 1990
39. Yancik R, Havlik RJ, Wesley MN, et al: Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 6:399-412, 1996
40. Yancik R, Wesley MN, Ries LA, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 82:2123-2134, 1998
41. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001
42. Read WL, Tierney RM, Page NC, et al: Differential prognostic impact of comorbidity. J Clin Oncol 22:3099-3103, 2004
43. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
44. Solomon D, Sue BA, Brummel-Smith K, et al: Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement - Geriatric assessment methods for clinical decision-making, 1988. J Am Geriatr Soc 51:1490-1494, 2003
45. Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the international Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-252, 2005
46. Repetto L, Venturino A, Vercelli M, et al: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 82:760-765, 1998
47. Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471, 2000
48. Min LC, Elliott MN, Wenger NS, et al: Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc 54:507-511, 2006
49. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005
50. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
51. Trimble EL, Carter CL, Cain D, et al: Representation of older patients in cancer treatment trials. Cancer 74:2208-2214, 1994
52. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 341:2061-2067, 1999
53. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital caner programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002
54. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003
55. Lee SJ, Lindquist K, Segal MR, et al: Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295:801-808, 2006
56. Cohen HJ, Harris T, Pieper CF: Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180-187, 2003
57. Ferrucci L, Corsi A, Lauretani F, et al: The origins of age-related proinflammatory state. Blood 105:2294-2299, 2005
58. Hainsworth JD, Carrell D, Drengler RL, et al: Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: A Minnie Pearl Cancer Research Network phase II trial. Cancer 100:2437-2441, 2004
59. Jatoi A, Hillman S, Stella P, et al: Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 23:9113-9119, 2005
60. George SL: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996